Audit: QRS - Potassium for Health & Longevity
Audit conducted on 26/06/2026 03:40 using AI4L / Opus 4.8
Summary
| Items | Count |
|---|---|
| Total | 71 |
| Passed | 71 |
| Failed | 0 |
| N/A | 0 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All content traces to the ER. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Cautious framing (“main danger”, “reserved for specific needs”) preserved. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening detected. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications, interactions, benefits, risks map to their ER categories. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No citations, NCT IDs, or brand names appear in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No new attributions introduced. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Tone matches ER. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Achieved. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents evidence, not prescriptions. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No directive medical advice. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Information-presenting voice throughout. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person address. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain language used. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Compact throughout. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | No “you” usage. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing matches audience. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Food-first dietary effort reflected. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not aimed at general population. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Risk/benefit weighting reflects audience. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging”. Proper names that contain “anti-aging” are quoted verbatim. | 🟢 | No “anti-aging” usage. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language. Direct quotes from sources are exempt. | 🟢 | Formal terminology used. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings (“Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”); Gate headings (“Contraindications”, “Key Interactions”); Tier labels (“High”, “Medium”, “Low”, “Speculative”); Table column headers in Monitoring (“Marker”, “Target”, “Why”). | 🟢 | All fixed headings present and unmodified. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All variable spans present, including hidden time_2/time_3 sets. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Untouched spans unchanged. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | 🟢 | No empty source sections required empty-state phrasing. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Monitoring marker names map verbatim to ER biomarker rows. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Row/cell labels not invented. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji indicators in QRS. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Content condensed to one page. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Metadata comment is first element (lines 2–14). |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | YAML delimited by — on lines 3 and 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Inside HTML comment; not rendered. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Values trimmed; only duration quoted (contains colon). |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: potassium_2026-0626-0219_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.5.18. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” | 🟢 | qrs_creation_date: 2026-0626-0219. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. | 🟢 | “Opus” — single word. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 4.8. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier | 🟢 | “Opus 4.8” — nickname plus version only. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: potassium_2026-0626-0219_Opus_QRS.html. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Values trimmed and correctly quoted. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet”. The [canonical_topic] is HTML-entity-encoded as needed. | 🟢 | “Potassium for Health & Longevity - Quick Reference Sheet”. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed. | 🟢 | “Potassium for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | “06/26/2026” from 2026-0626. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | “Opus 4.8”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header has only title and subline. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Distills the Conclusion (lines 430–434). |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each fact maps to the Conclusion. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | Plain language; “blood potassium” not “hyperkalemia”. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trials cited. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No statistics cited. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Derived from that section (line 296). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | Matches the “populations who should avoid” list plus K-sparing diuretics. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Each item is an <li>. |
| 8.4 | Items are as concise as possible. No trailing explanations, elaborations, mechanistic rationale, attributions, citations, study details. No content after an em-dash, en-dash, or hyphen-dash. Just the key fact. | 🟢 | Concise, no trailing clauses. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved, kept as concise as possible. | 🟢 | “(especially eGFR below ~45–60)” preserved. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase, normalize to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | No bare ranking symbols carried through. |
| 8.7 | If no [stop_items] are present the section is left empty | 🟢 | Items present; condition not triggered. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Derived from that section. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | K-sparing diuretics (contraindication) excluded; others present. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Each item is an <li>. |
| 9.4 | Items are as concise as possible. No trailing explanations, elaborations, mechanistic rationale, attributions, citations, study details. No content after an em-dash, en-dash, or hyphen-dash. Just the key fact. | 🟢 | Concise, no trailing clauses. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved, kept as concise as possible. | 🟢 | Example drug lists (lisinopril, losartan, etc.) preserved. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase, normalize to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | No bare ranking symbols carried through. |
| 9.7 | If no [caution_items] are present the section is left empty | 🟢 | Items present; condition not triggered. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Cells derive from the Therapeutic Protocol section. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Food-first, target intake, targeted supplementation — the three protocol approaches. |
| 10.3 | If less than three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible. | 🟢 | All three sets used; condition not triggered. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All cells filled with ER-derived content. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | ER provides only one time-to-effect aspect (blood pressure). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Single set is the highest-magnitude benefit (blood pressure). |
| 11.3 | If less than three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | 🟢 | time_2/time_3 emptied and display:none. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | time_1 filled from Practical Considerations (line 369). |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
🟢 | ER provides time-to-effect; section retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Derived from Expected Benefits. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four tiers populated. |
| 12.3 | Items are as concise as possible. No explanations, elaborations, effect sizes, qualifiers, attributions, citations, study details, mechanistic explanations, etc. Just the key fact. | 🟢 | Tier items are bare facts. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | “(via Salt Substitution)” stripped from medium tier. |
| 12.5 | If no items of a specific sub-section are present the respective is set to “display=none”, not filled with empty-state phrasing. | 🟢 | All tiers have ER content; condition not triggered. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Derived from Potential Risks & Side Effects. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four tiers populated. |
| 13.3 | Items are as concise as possible. No explanations, elaborations, effect sizes, qualifiers, attributions, citations, study details, mechanistic explanations, etc. Just the key fact. | 🟢 | Tier items are bare facts. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | “(Dangerously High Blood Potassium)” stripped to “Hyperkalemia”. |
| 13.5 | If no items of a specific sub-section are present the respective is set to “display=none”, not filled with empty-state phrasing. | 🟢 | All tiers have ER content; condition not triggered. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from Monitoring Protocol & Defining Success. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All five biomarkers (serum K, eGFR, BP, 24-h urinary K, serum Mg) listed. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Cadence populated from ER lines 393–395. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the qualitative markers list (lines 407–410). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All four ER qualitative markers (lines 407–410) appear verbatim in qualitative_item_1–4. |
Issues 26/06/2026 03:40
Pass rate 100.00%. No issues found.
Issues 26/06/2026 03:35
- 13.3 — Parenthetical gloss in high risk: risks_high (line 569) keeps “Hyperkalemia (dangerously high blood potassium)”; per 13.3 the tiered item must be reduced to the key fact, with the parenthetical elaboration stripped.
Fixes 26/06/2026 03:35
- 13.3 — Stripped parenthetical from high risk: Changed risks_high from “Hyperkalemia (dangerously high blood potassium); gastrointestinal irritation from supplements” to “Hyperkalemia; gastrointestinal irritation from supplements”, removing the definitional gloss so the tiered item carries only the key fact.
Issues 26/06/2026 03:31
- 9.4 — Supplement-interaction elaboration not stripped: The 5th Key Interactions item retains an explanatory parenthetical “(electrolyte and "greens" supplements, magnesium with potassium, high-dose blends)” (QRS line 555); these are mechanistic elaborations of the interaction rather than named example drugs, so the conciseness requirement is not fully met.
Fixes 26/06/2026 03:31
- 9.4 — Supplement-interaction elaboration condensed: Trimmed the 5th Key Interactions item from “(electrolyte and "greens" supplements, magnesium with potassium, high-dose blends)” to “(hidden potassium in electrolyte, "greens", and high-dose blends)”, condensing the mechanistic elaboration to the key fact.
Issues 26/06/2026 03:26
- 11.3 — Empty time cells not hidden: The unused time_2 and time_3 sets (QRS lines 492–513) have empty spans but their containing
.pcelldivs are not made invisible, so two empty grid cells render in the Time to Effect row instead of being hidden.
Fixes 26/06/2026 03:26
- 11.3 — Hide empty time cells: Added
style="display: none"to the unused time_2 and time_3.pcelldivs (QRS lines 492 and 503) so the two empty Time to Effect grid cells no longer render.
Issues 26/06/2026 03:20
- 12.3 / 12.4 — Mechanistic qualifier not stripped: benefits_medium (QRS line 525) retains the parenthetical “(via salt substitution)” on “Lower cardiovascular event and mortality risk”; this mechanistic qualifier must be stripped per 12.3/12.4.
Fixes 26/06/2026 03:20
- 12.3 / 12.4 — Mechanistic qualifier stripped: Removed the parenthetical “(via salt substitution)” from the Medium benefit, changing it to “Lower cardiovascular event and mortality risk”.
Issues 26/06/2026 03:17
- 7.2 — At-a-glance exceeds word limit: The at_a_glance text (line 433) is 61 words, exceeding the 60-word maximum by one word.
Fixes 26/06/2026 03:17
- 7.2 — At-a-glance word limit: Trimmed the at_a_glance text from 61 to 59 words by changing “too much potassium in the blood” to “too much blood potassium”, bringing it within the 60-word maximum.